Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2020-04, Vol.21 (4), p.531-540
Hauptverfasser:	Hong, David S, DuBois, Steven G, Kummar, Shivaani, Farago, Anna F, Albert, Catherine M, Rohrberg, Kristoffer S, van Tilburg, Cornelis M, Nagasubramanian, Ramamoorthy, Berlin, Jordan D, Federman, Noah, Mascarenhas, Leo, Geoerger, Birgit, Dowlati, Afshin, Pappo, Alberto S, Bielack, Stefan, Doz, François, McDermott, Ray, Patel, Jyoti D, Schilder, Russell J, Tahara, Makoto, Pfister, Stefan M, Witt, Olaf, Ladanyi, Marc, Rudzinski, Erin R, Nanda, Shivani, Childs, Barrett H, Laetsch, Theodore W, Hyman, David M, Drilon, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescence Adolescent Adult Aged Aged, 80 and over Alanine Alanine transaminase Aspartate aminotransferase Breast cancer Cancer therapies Child Child, Preschool Clinical trials Disease control FDA approval Female Fibrosarcoma Genes Growth factors Humans Infant Infant, Newborn Laboratories Male Medical research Metastases Metastasis Middle Aged Nausea Neoplasms - chemistry Neoplasms - drug therapy Oncology Oral administration Patients Proteins - analysis Pyrazoles - therapeutic use Pyrimidines - therapeutic use Safety Solid tumors Studies Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!